Want to see OCGN full AI Analyst Report?
OCGN Stock Chart & Stats
$1.41
$0.05(4.13%)
At close: 4:00 PM EDT
$1.41
$0.05(4.13%)
Day’s Range― - ―
52-Week Range$0.69 - $2.73
Previous Close$1.26
Volume5.01M
Average Volume (3M)7.13M
Market Cap
$238.29M
Enterprise Value$506.12M
Total Cash (Recent Filing)$100.05M
Total Debt (Recent Filing)$87.99M
Price to Earnings (P/E)―
Beta1.06
Next Earnings
Nov 04, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding339,110,400
10 Day Avg. Volume6,751,179
30 Day Avg. Volume7,127,816
Financial Highlights & Ratios
PEG Ratio-0.39
Price to Book (P/B)-33.31
Price to Sales (P/S)91.83
P/FCF Ratio-7.09
Enterprise Value/Market Cap2.12
Enterprise Value/Revenue110.51
Enterprise Value/Gross Profit110.51
Enterprise Value/Ebitda-7.22
Forecast
1Y Price Target
$10.20Price Target Upside623.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.26
Revenue Forecast (FY)$4.96M
Bulls Say, Bears Say
Bulls Say
Regulatory And Clinical ProgressFDA clearance and RMAT designation move OCU410 into a registrational Phase 3 pathway for geographic atrophy. This reduces some development uncertainty, creates defined regulatory milestones, and gives the company a credible route toward a potential BLA submission.
Regional Partnership EconomicsThe Roots agreement expands OCU400’s commercial reach without requiring Ocugen to build the entire regional infrastructure alone. Upfront, milestone, supply and royalty provisions could create future non-dilutive economics if development and commercialization milestones are achieved.
Manufacturing ReadinessCompleted process performance qualification batches provide an important operational foundation for potential approval and launch. Manufacturing readiness can help connect clinical success to commercial execution, reduce a key late-stage development hurdle, and support planned regulatory filings.
Bears Say
Negative Equity And Higher DebtNegative equity combined with sharply higher debt materially reduces financial flexibility. The capital structure leaves less capacity to absorb setbacks or fund programs internally, while increasing refinancing pressure and the likelihood that future capital needs may affect existing shareholders.
Persistent Cash BurnOcugen remains dependent on external funding because operating activities do not yet generate cash and free cash flow is deeply negative. Continued spending across three late-stage programs may consume substantial resources before any product revenue or milestone receipts become dependable.
Rising Operating CostsHigher R&D and G&A spending reflects the cost of advancing the pipeline but increases the funding burden while revenue remains limited. If expense growth continues ahead of commercial or partnership receipts, losses and financing requirements could remain elevated through development.
Ocugen News
OCGN FAQ
What was Ocugen Inc’s price range in the past 12 months?
Ocugen Inc lowest stock price was $0.69 and its highest was $2.73 in the past 12 months.
What is Ocugen Inc’s market cap?
Ocugen Inc’s market cap is $238.29M.
When is Ocugen Inc’s upcoming earnings report date?
Ocugen Inc’s upcoming earnings report date is Nov 04, 2026 which is in 3 days.
How were Ocugen Inc’s earnings last quarter?
Ocugen Inc released its earnings results on Aug 06, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.053 by -$0.017.
Is Ocugen Inc overvalued?
According to Wall Street analysts Ocugen Inc’s price is currently Undervalued.
Does Ocugen Inc pay dividends?
Ocugen Inc does not currently pay dividends.
What is Ocugen Inc’s EPS estimate?
Ocugen Inc’s EPS estimate is -0.06.
How many shares outstanding does Ocugen Inc have?
Ocugen Inc has 339,110,400 shares outstanding.
What happened to Ocugen Inc’s price movement after its last earnings report?
Ocugen Inc reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.053. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Ocugen Inc?
Currently, no hedge funds are holding shares in OCGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocugen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.20 (623.40% Upside)
$10.20 (623.40% Upside)
Blogger Sentiment
Bullish
OCGN Sentiment 75%
Sector Average 64%
Sector Average 64%
Crowd Wisdom
Negative
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.56%
12-Months-Change
Fundamentals
Return on Equity
1688.22%
Trailing 12-Months
Asset Growth
131.75%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Ocugen Inc
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
OCGN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed multiple significant clinical and regulatory advances — FDA clearance to start the Phase 3 GA trial with RMAT designation, strong Phase II efficacy signals for OCU410, completed enrollments and clear timelines for Phase III readouts for OCU400 and OCU410ST, manufacturing PPQs complete, a $130M financing and cash runway into 2028, and a MENA partnership — all material execution milestones. Offsetting these positives are rising operating expenses and a larger reported net loss per share, continued dependence on additional financing levers (which could be dilutive), and customary regulatory/timing and commercialization uncertainties. Overall, the operational and clinical progress and strengthened balance sheet outweigh the financial and execution risks discussed on the call.View all OCGN earnings summariesOCGN Stock 12 Month Forecast
Average Price Target
$10.20
▲(623.40% Upside)
Technical Analysis
Ownership Overview
2.34% Insiders
8.34% Mutual Funds
1.27% Other Institutional Investors
74.06% Public Companies and
Individual Investors